Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 5.74 EUR -1.03% Market Closed
Market Cap: 160.7m EUR
Have any thoughts about
Hyloris Pharmaceuticals SA?
Write Note

Hyloris Pharmaceuticals SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hyloris Pharmaceuticals SA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Hyloris Pharmaceuticals SA
XBRU:HYL
Interest Income Expense
€514k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ucb SA
XBRU:UCB
Interest Income Expense
-€151m
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Financiere de Tubize SA
XBRU:TUB
Interest Income Expense
€185.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hyloris Pharmaceuticals SA
Glance View

Market Cap
160.7m EUR
Industry
Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.

HYL Intrinsic Value
4.38 EUR
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Hyloris Pharmaceuticals SA's Interest Income Expense?
Interest Income Expense
514k EUR

Based on the financial report for Dec 31, 2023, Hyloris Pharmaceuticals SA's Interest Income Expense amounts to 514k EUR.

Back to Top